Karyopharm Therapeutics I... (KPTI)
NASDAQ: KPTI
· Real-Time Price · USD
6.88
-0.60 (-8.02%)
At close: Sep 24, 2025, 3:59 PM
6.56
-4.64%
After-hours: Sep 24, 2025, 05:37 PM EDT
-8.02% (1D)
| Bid | 6.3 |
| Market Cap | 59.66M |
| Revenue (ttm) | 137.27M |
| Net Income (ttm) | -123.57M |
| EPS (ttm) | -14.84 |
| PE Ratio (ttm) | -0.46 |
| Forward PE | -0.75 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7 |
| Volume | 145,020 |
| Avg. Volume (20D) | 174,620 |
| Open | 7.68 |
| Previous Close | 7.48 |
| Day's Range | 6.80 - 7.82 |
| 52-Week Range | 3.51 - 16.95 |
| Beta | 0.35 |
| Ex-Dividend Date | n/a |
About KPTI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KPTI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KPTI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsKaryopharm Therapeutics Inc. is scheduled to release its earnings on
Nov 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-20%
Karyopharm Therapeutics shares are trading lower a...
Unlock content with
Pro Subscription
10 months ago
+17.86%
Karyopharm Therapeutics shares are trading higher after the company announced that, following the FDA feedback, it will be replacing TSS50, one of the co-primary endpoints in the Phase 3 SENTRY Trial with Abs-TSS.
1 month ago · seekingalpha.com
Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call TranscriptKaryopharm Therapeutics Inc. (NASDAQ:KPTI ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Brendan Twohig Strong - Corporate Participant SVP of Investor Relations & Corporate Co...
